Figure 2. Target inhibition by carfilzomib.

Chymotrypsin-like proteasome activity was measured in CLL cells from whole blood obtained at screening, pre-treatment, and post-treatment day 1, pre-treatment day 2, and pre and post-treatment day 8 using a commercial assay. Proteasome activity in each sample is shown relative to the activity in that patient's pretreatment sample.